Last reviewed · How we verify

abacavir/lamivudine + raltegravir — Competitive Intelligence Brief

abacavir/lamivudine + raltegravir (abacavir/lamivudine + raltegravir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI/INSTI combination. Area: Infectious Diseases.

phase 3 NRTI/INSTI combination Reverse transcriptase/Integrase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

abacavir/lamivudine + raltegravir (abacavir/lamivudine + raltegravir) — University of Modena and Reggio Emilia. Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
abacavir/lamivudine + raltegravir TARGET abacavir/lamivudine + raltegravir University of Modena and Reggio Emilia phase 3 NRTI/INSTI combination Reverse transcriptase/Integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI/INSTI combination class)

  1. University of Modena and Reggio Emilia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). abacavir/lamivudine + raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/abacavir-lamivudine-raltegravir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: